Network Version
Eribulin mesylate Data Sheet
| Product Name: | Eribulin mesylate |
 |
|---|---|---|
| CAS No.: | 441045-17-6 | |
| Cat. No.: | HY-13442A | |
| MWt: | 826.0 | |
| Formula: | C41H63NO14S | |
| Purity : | >98% | |
| Solubility: | DMSO : ≥ 100 mg/mL (121.07 mM); Ethanol : ≥ 100 mg/mL (121.07 mM) | |
| Mechanisms: | Target: Cancer | |
| Biological Activity: | ||
|
Eribulin (E7389) mesylate is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin mesylate inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.
In Vitro: Eribulin mesylate (1-100 nM; 72 h) inhibits cells proliferation, with IC50s of 22.8 and 21.5 nM for LM8 and Dunn cells, respectively[1]. Eribulin mesylate (10-50 nM; 12-72 h) increases early apoptosis significantly after 24 h treatment at the dose of 50 nM in LM8 cells[1]. Eribulin mesylate (10-50 nM; 12-72 h) induces G2/M arrest by 12 h treatment with at the dose of 50 nM, but not by long-term treatment (72 h) with 10 nM in LM8 cells[1]. Eribulin mesylate (1-50 nM; 12 h) does not induce senescence in LM8 cells[1]. Eribulin mesylate (1-10 nM; 16 h) induces morphological change and suppresses cell migration in a low concentration in LM8 cells[1]. In Vivo: Eribulin mesylate (1 mg/kg; i.v. once a week for 2 weeks) reduces primary tumor growth and lung metastasis of osteosarcoma in mice[1]. Eribulin mesylate (1 mg/kg; once i.v.) suppresses circulating tumor cells (CTC) appearance in the low-concentration phase[1]. |
||
1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA
Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com